“Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study”, jkcvhl, vol. 12, no. 4, pp. 7–18, Oct. 2025, doi: 10.15586/jkcvhl.v12i4.403.